Key regions: Australia, Japan, United States, Germany, Europe
The Anti-Coagulants market is a rapidly growing sector in the healthcare industry.
Customer preferences: The increasing prevalence of cardiovascular diseases along with the rise in the aging population has resulted in a higher demand for anti-coagulants. Patients are preferring anti-coagulants due to their effectiveness in preventing blood clots and reducing the risk of stroke.
Trends in the market: In the United States, the anti-coagulants market has witnessed a shift towards the use of Non-Vitamin K Oral Anticoagulants (NOACs) from Warfarin due to their ease of use and lower risk of bleeding. In Europe, there has been a rise in the use of Direct Oral Anticoagulants (DOACs) due to their efficacy in treating various coagulation disorders. The Asia-Pacific region is also showing a significant growth in the anti-coagulants market due to the increasing incidence of cardiovascular diseases and the rise in healthcare expenditure.
Local special circumstances: In China, the anti-coagulant market is dominated by local players due to the government's push towards domestic manufacturing and the availability of low-cost generic drugs. In India, the anti-coagulant market is highly fragmented with the presence of both multinational and local players. The market is driven by the increasing incidence of cardiovascular diseases and the rise in healthcare expenditure.
Underlying macroeconomic factors: The global anti-coagulants market is being driven by the increasing prevalence of cardiovascular diseases, rising geriatric population, and the growing demand for NOACs and DOACs. The market is also being propelled by the increasing healthcare expenditure and the rise in awareness about the benefits of anti-coagulants. However, the market is also facing challenges such as the high cost of NOACs and DOACs, the risk of bleeding, and the availability of low-cost generic drugs. The market is also being impacted by the COVID-19 pandemic as the focus shifts towards the treatment of the virus, resulting in a decline in demand for non-essential drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
